Navigation Links
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
Date:12/6/2008

ituximab plus dexamethasone.

The primary objective of the study was to compare the sustained response (platelet counts greater than or equal to 50 x 10^9/L from one month to six months from the beginning of therapy) between the two treatment groups. Secondary objectives included overall safety, initial response (platelet count of 50 x 10^9/L after 30 days of treatment), activity of the salvage therapy (dexamethasone/rituximab) in patients not responding to dexamethasone alone, the identification of clinical and laboratory factors predictive of response, and the pharmacokinetic parameters of rituximab (the level of rituximab circulating in the blood of patients during the study period) and their potential relation to response.

The researchers examined the results for all enrolled patients, regardless of whether or not they completed the study (intention-to-treat basis, ITT), and on a per-protocol (PP) basis, examining those who had completed the treatment regimen. The ITT group included 52 patients treated with dexamethasone alone and 49 treated with rituximab/dexamethasone. The PP group included 38 patients treated with dexamethasone alone and 26 treated with rituximab/dexamethasone. ITT and PP sustained response rates were 63 percent and 85 percent in the rituximab/dexamethasone combination arm as compared with 36 percent and 39 percent in the dexamethasone-alone arm.

A total of 27 patients who failed to achieve an initial or sustained response in the dexamethasone-alone arm received the salvage treatment. In this group, ITT and PP sustained response rates were 56 percent and 59 percent, respectively.

No clinical or laboratory factors predictive of a sustained response were identified in the study. There was a mild increase in the incidence of severe adverse events in the dexamethasone-plus-rituximab arm (2 percent in dexamethasone arm versus 6 percent in dexamethasone-plus-rituxima
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today ... increased the purchase price of its previously announced "Modified ... to purchase, for cash, up to $65,000,000 aggregate principal ... 2.875% Senior Subordinated Convertible Notes due 2010. , The ...
... DIEGO, Nov. 9, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... 30, 2009. , Arena reported a lower net loss allocable to ... or $0.38 per share, compared to a net loss allocable to ... or $0.76 per share, and a net loss allocable to common ...
Cached Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , Statement of Esta Soler, President, Family Violence Prevention Fund , ... today in Los Angeles in the domestic violence case involving Chris ... like this. Despite what was apparently an extremely violent assault, ... remained a felony, and that Mr. Brown pleaded guilty, taking responsibility ...
... , LOS ANGELES, June 22 Mission Viejo general surgeon ... the newly-elected Chair of the Mutual Protection Trust (MPT) Board ... the Cooperative of American Physicians, Inc. (CAP). Dr. Cobo,s election ... J. Michael Wormley, MD, a Glendora family practitioner who presided ...
... isolated a potent inhibitor of tumor metastasis made by tumor ... treatment. Their findings were published in the online Early Edition ... during the week of June 22. Metastasisthe ... one of the leading causes of death from cancer, and ...
... Tarzana Medical Center on Friday became the first. hospital in the ... Vision RFD - in this case to aid a surgeon in ... a small stroke. , , Zahi E. Nassoura, a board-certified ... saw in the crystal-clear image provided by the Ziehm Vision, approved ...
... misdiagnosis as the likely cause of apparent uptick in melanoma ... released study in the June 2009 British Journal of Dermatology ... United Kingdom has concluded that the much-hyped melanoma "epidemic" is ... attributed the increase in melanoma diagnoses to heightened sensitivity and ...
... The Department of Veterans Affairs (VA) has initiated a large, ... health issues that may affect Operation Enduring Freedom/Operation Iraqi Freedom ... time period. VA,s "National Health Study for a New ... to OEF/OIF and 30,000 comparison Veterans who were not deployed. ...
Cached Medicine News:Health News:Domestic Violence Expert Comments on Chris Brown Plea Deal 2Health News:Dr. Juan Carlos Cobo Newly-Elected Chair of the Mutual Protection Trust Board of Trustees 2Health News:Potent metastasis inhibitor identified 2Health News:Providence Tarzana Surgeon First in U.S. to Use New State-of-the-Art Imaging Tool 2Health News:New Study Says Purported Melanoma Epidemic is Vastly Overstated 2Health News:VA Launches 10-Year Health Study of 60,000 New Veterans 2
Test for prostatic acid phosphatase...
... you could imagine the ultimate OR, how ... efficiency? Would its control systems be intuitive? ... to quickly adapt to different tasks and ... longer need to imagine this environment. It's ...
... is the world's first Windows ... measuring system. It allows data sharing ... is compatible with Microsoft Office 2000. ... see on the large, sharp 14.1-inch ...
... T-series is a new top-line range of ... and Atrial Fibrillation (AF). Because the T-series ... AF, the treatment of AF is taken ... technology the heart rhythm is monitored continuously ...
Medicine Products: